Physician profile
Joel M Oster
NPI 1881794873
$5,720.05
in general payments reported to CMS, 2019-2025
29 companies · $614 in 2025
The $614 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,533 · 2020: $533 · 2021: $215 · 2022: $276 · 2023: $766 · 2024: $783 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,162.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,232.34 | 2019-2025 | Fintepla, Briviact, Rystiggo |
| Sunovion Pharmaceuticals INC. | $693.90 | 2019-2020 | |
| Neuropace, INC. | $673.48 | 2019-2025 | |
| Livanova USA, INC. | $422.47 | 2019 | |
| Sk Life Science, INC. | $395.95 | 2020-2025 | |
| Zoll Respicardia, INC. | $342.34 | 2023-2024 | Remede System |
| Teva Pharmaceuticals USA, INC. | $237.91 | 2019 | |
| Itamar Medical INC | $219.91 | 2022-2023 | Watchpatone |
| Biogen, INC. | $199.85 | 2019-2025 | Tysabri |
| Emd Serono, INC. | $165.82 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $146.05 | 2019-2020 | |
| Inspire Medical Systems, INC. | $140.94 | 2019-2023 | Inspire |
| Eisai INC. | $124.99 | 2025 | |
| Neurocrine Biosciences, INC. | $106.19 | 2021 | |
| Janssen Pharmaceuticals, INC | $104.19 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $78.88 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $73.19 | 2019 | |
| Allergan, INC. | $66.95 | 2019 | |
| Acorda Therapeutics, INC | $41.21 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.91 | 2020 | |
| Zimmer Biomet Holdings, INC. | $36.22 | 2022 | |
| Portola Pharmaceuticals, LLC | $36.10 | 2019 | |
| Monteris Medical Corporation | $34.06 | 2022 | |
| Grifols USA, LLC | $21.67 | 2020 | |
| Boston Scientific Corporation | $20.73 | 2019 | |
| Csl Behring | $20.45 | 2020 | |
| Genentech USA, INC. | $18.04 | 2025 | Ocrevus Zunovo |
| Avanir Pharmaceuticals, INC. | $17.25 | 2019 | |
| Novocure INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Oster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.